# Kimberly-Clark completes Kenvue acquisition

> Kimberly-Clark closes $49 billion Kenvue deal, adding Tylenol to portfolio.
- Title: Kimberly-Clark completes Kenvue acquisition · CNBC | Shortify
- Summary: Kimberly-Clark closes $49 billion Kenvue deal, adding Tylenol to portfolio. Kimberly-Clark finalized its $49 billion acquisition of Kenvue, the Tylenol…
- Keywords: kimberly-clark, kenvue, tylenol, acquisition, health and wellness, dividend aristocrat, michael hsu, jim cramer, investing club, dividend yield, inflation, legal troubles
- Source: CNBC — https://cnbc.com/investingclub/2026/11/02/kimberly-clark-closes-its-acquisition-of-tylenol-maker-kenvue-what-to-expect-next.html
- Author: Natasha Abellard
- Published: 2026-11-02T21:35:06+00:00
- Read time: 1 min
- Topics: kimberly-clark, kenvue, tylenol, acquisition, health and wellness, dividend aristocrat, michael hsu, jim cramer, investing club, dividend yield, inflation, legal troubles
## Acquisition completion
Kimberly-Clark completed its acquisition of Kenvue, the Tylenol maker, on Monday.
## Strategic expansion
The deal broadens Kimberly-Clark's reach into health and wellness as consumers prioritize healthy lifestyles.
## Stock performance
Shares rose 0.3% to $108.25 after closing the acquisition at almost $49 billion.
## Financial targets
Kimberly-Clark aims for $1.9 billion in cost reductions and $500 million in incremental profits within three years.
## Integration challenges
Kimberly-Clark faces questions about integrating Kenvue, managing higher input costs, and handling Tylenol legal issues.
## CEO vision
Michael Hsu emphasized strengthening Kenvue's operations and accelerating growth in health products.
## Product growth
Hsu noted significant growth potential in Kenvue's product categories including Tylenol, Band-Aid, and Neutrogena.
## Inflation management
Kimberly-Clark plans to offset higher input costs while keeping prices affordable for lower-income consumers.
## Tylenol legal issues
Tylenol faces litigation over pregnancy use linked to autism and ADHD claims.
## Dividend commitment
Kimberly-Clark maintains its dividend aristocrat status with a 4.73% yield and plans to keep dividends safe.
## Future outlook
Hsu expects earnings to be accretive by year two and leverage to drop to 2.0 by reducing debt.
## Key takeaway

Kimberly-Clark finalized its $49 billion acquisition of Kenvue, the Tylenol maker, to expand into health and wellness with plans to integrate operations and manage legal risks.